Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Enantioselective Construction of Aza-bicyclo[3.2.1]octane Skeletons via Substituted π-Allyl Palladium Dipoles Originated from Neutral η3-Propargyl Palladium Species.

Created on 04 Aug 2025

Authors

Yong-Jie Long, Yin Wei, Min Shi

Published in

Journal of the American Chemical Society. Aug 04, 2025. Epub Aug 04, 2025.

Abstract

A catalytic strategy for insitu generation of substituted π-allyl palladium dipoles from neutral η3 -propargyl palladium complexes has been disclosed, enabling the construction of enantiomerically enriched aza-bicyclo[3.2.1]octane frameworks through cascade cyclization reactions based on neutral zwitterionic π-propargyl palladium species derived from vinylidenecyclopropane-diesters (VDCP-diesters) and their analogues. This protocol demonstrates remarkable synthetic efficiency under mild reaction conditions, achieving moderate to good yields (42 examples) with excellent stereochemical control (>90% ee in most cases). This asymmetric catalytic reaction can be applied in a series of semigram-scale manipulations, and the obtained cycloadducts can be transformed into diverse functionalized products while retaining excellent enantioselectivities. On the basis of mechanistic investigations and DFT calculations, the critical "palladacyclobutenization-protonolysis" sequence has been elucidated as the pivotal chirality-determining step in the whole plausible reaction pathway.

PMID:
40758216
Bibliographic data and abstract were imported from PubMed on 04 Aug 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 45
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement